From hepatocellular carcinoma and renal cell carcinoma analyses, higher baseline plasma levels of IL‐8 were correlated with worse outcomes in treatment with angiogenesis inhibitors, such as sunitinib or BEV. The gene discussed is CXCL8; the disease is hepatocellular carcinoma.